| 000 | 03642nam a2200445 i 4500 | ||
|---|---|---|---|
| 999 |
_c127451 _d127451 |
||
| 001 | 127451 | ||
| 003 | ES-MaUEC | ||
| 005 | 20230102114249.0 | ||
| 006 | a||||fo|||| 00| 0 | ||
| 007 | cr nn nnnaamaa | ||
| 008 | 200907s2020 gw a s |||| 0|eng d | ||
| 020 | _a9783030506216 | ||
| 024 | 7 |
_a10.1007/978-3-030-50621-6 _2doi |
|
| 040 |
_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC |
||
| 050 | 4 |
_aQH506 _b2020 EB |
|
| 245 | 0 | 0 |
_aDruggable Lipid Signaling Pathways _cedited by Yasuyuki Kihara |
| 250 | _aFirst edition 2020 | ||
| 264 | 1 |
_aCham _bSpringer International Publishing _c2020 |
|
| 300 |
_a1 recurso en línea (VI, 260 páginas) _b33 ilustraciones, 21 ilustraciones a color |
||
| 336 |
_2rdacontent _aTexto _btxt |
||
| 337 |
_2rdamedia _aelectrónico _bc |
||
| 338 |
_2rdacarrier _arecurso electrónico _bcr |
||
| 347 |
_aArchivo de texto _bPDF |
||
| 490 | 0 |
_aAdvances in Experimental Medicine and Biology _x0065-2598 _v1274 |
|
| 490 | 0 | _aBiomedical and Life Sciences (SpringerNature-11642) | |
| 490 | 0 | _aBiomedical and Life Sciences (SpringerNature-43708) | |
| 505 | 0 | _aPreface -- Introduction of Druggable Lipid Signaling Pathway -- Biosynthetic Enzymes of Membrane Glycerophospholipid Diversity as Therapeutic Targets for Drug Development -- Druggable Prostanoid Pathway -- Targeting Leukotrienes as a Therapeutic Strategy to Prevent Comorbidities Associated with Metabolic Stress -- Epoxy Fatty Acids are Promising Targets for Treatment of Pain, Cardiovascular Disease and Other Indications Characterized by Mitochondrial Dysfunction, Endoplasmic Stress and Inflammation -- Druggable Sphingolipid Pathway -- Druggable Lysophospholipid Pathway -- Druggable targets in endocannabinoid signaling -- Drugging the phosphoinositide 3-kinase (PI3K) and phosphatidylinositol 4-kinase (PI4K) family of enzymes for treatment of cancer, immune disorders, and viral/parasitic infections -- Druggable Lipid GPCRs: Past, Present, and Prospects | |
| 520 | 3 | _aThis edited work presents a series of reviews focusing on Druggable Lipid Signaling Pathways. It enables researchers in both academic institutions and industry as well as physicians to understand historical aspects of lipid signaling and future directions of drug discovery targeting lipid signaling pathways. This book provides 9 pathways including acyltransferases, prostanoids, leukotrienes, epoxy fatty acids, sphingolipids, lysophospholipids, endocannabinoids, phosphoinositides, and lipid GPCRs. Readers will discover the importance of each lipid signaling pathway that contributes to broad range of diseases including neurological and neuropsychiatric diseases, pain, metabolic syndromes, cardiovascular diseases, cancer, dermatological diseases, fibrosis, inflammation, etc. Also, readers will recognize that many drugs targeting lipid signaling have been clinically used. Drugs currently under development are also discussed in each chapter, which includes some information about clinical trials and strategic drug designs | |
| 988 | _aSpringer_BiomedLife_13102020 | ||
| 650 | 7 |
_2embne _aBiología molecular _9139103 |
|
| 650 | 7 |
_2embne _aLípidos _9142933 |
|
| 700 | 1 |
_aKihara, Yasuyuki _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt |
|
| 710 | 2 | _aSpringerLink | |
| 776 | 0 | 8 |
_iPrinted edition: _z9783030506209 |
| 776 | 0 | 8 |
_iPrinted edition: _z9783030506223 |
| 776 | 0 | 8 |
_iPrinted edition: _z9783030506230 |
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-50621-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 942 |
_2lcc _cLE |
||
| 998 |
_b01/2021 _dz _ek _zSI |
||